The Latest Breaking News from Cholesterol

The FDA recalls over 140,000 bottles of Atorvastatin after failed quality tests. Find out which products are affected and what patients should do next.

The tablets were distributed nationwide in up to 1,000-count bottles

Medical school might be the gold standard for training doctors—but when it comes to nutrition, some of what’s being taught is straight out of the 1980s. You’d think the people who save lives for a living would get the most cutting-edge dietary education, right? Unfortunately, that’s not the case.

Here are some short and long-term impacts that excessive sugar consumption can have on your heart…

When we think about heart health, we often focus on big things like exercise and quitting smoking. These are incredibly important. However, what we put into our grocery cart each week has a massive, direct impact on our cardiovascular system. Many common foods, even some marketed as ‘healthy,’ are silently…

Shares of Sunshine Biopharma Inc. (NASDAQ:SBFM) are trading higher Thursday after the Florida-based pharmaceutical company announced the launch of a generic prescription drug.

A vaccine-skeptic doctor says the president should come off statins and aspirin – sparking an angry response from the White House

Heart disease remains the leading cause of death for older adults in the U.S., yet many daily eating habits quietly raise the risk. Even seemingly...

You might think heart attacks and strokes hit out of nowhere, striking healthy people without warning. But the latest study shows that over 99% of these events share common, detectable roots. That’s huge, because if we identify and address those hidden causes early, many tragedies are preventable. Understanding what drives…

How fiber could be your secret weapon for managing menopause

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals, Inc.’s (NASDAQ: REGN) Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of children from age 1 to less than 5 years old with homozygous familial hypercholesterolemia (HoFH).